Septerna Launches With $100 Million Series A Financing To Expand The Frontier Of Gpcr-Targeted Medicines Using The Native Complex™ Platform
Amount Raised
$100 Million
Round Type
Series A
San FranciscoBiotechnologyHealth CareScience And EngineeringDescription
Septerna, Inc., a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced its launch and Series A financing of $100 million. The Series A financing was led by Third Rock Ventures with significant support by Samsara BioCapital, BVF Partners, Invus Financial Advisors, Catalio Capital Management, Casdin Capital and Logos Capital. Septerna’s proprietary Native ComplexTM Platform recapitulates GPCRs with their native structure, function, and dynamics outside of the cellular environment which enables industrial-scale drug discovery using novel screening technologies and structure-based drug design for the first time. Septerna is using the Native ComplexTM to overcome historic challenges of reaching the vast untapped potential of GPCR drug targets for a wide range of diseases.
Quick answer
Septerna raised $100 Million in a Series A round, dated January 27, 2022. Septerna is based in San Francisco, California, United States.
- How much did Septerna raise?
- Septerna raised $100 Million in a Series A round on January 27, 2022.
- What does Septerna do?
- Septerna, Inc., is a biotechnology company creating broad new drug discovery opportunities across many disease areas for the abundant drug target class of G protein-coupled receptors (GPCRs).
- Where is Septerna based and how big is it?
- Septerna is based in San Francisco, California, United States.
- Who are the decision-makers at Septerna?
- Fundz holds 1 contact at Septerna. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Biotechnology around the same time
Companies in the same sectors as Septerna that raised within 45 days of this round, from Fundz verified event records.
- Psilera raised an undisclosed amount (Funding Round) on March 8, 2022.
- Sherlock Biosciences raised $80M (Series B) on March 8, 2022.
- Walking Fish Therapeutics raised $13M on March 3, 2022.
- SeLux Diagnostics, Inc. raised $50M (Series C) on February 28, 2022.
- Appili Therapeutics Inc. raised $10M (Funding Round) on February 28, 2022.
- Synthego Corp raised $200M (Funding Round) on February 17, 2022.
Who to call at Septerna, and when
A new round usually means Septerna is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Septerna raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Septerna, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Septerna. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Septerna raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansSepterna raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.